M Hummer

Summary

Affiliation: University of Innsbruck
Country: Austria

Publications

  1. ncbi request reprint Osteoporosis in patients with schizophrenia
    Martina Hummer
    Department of Biological Psychiatry, Innsbruck University Hospital, Austria
    Am J Psychiatry 162:162-7. 2005
  2. ncbi request reprint Sexual disturbances during clozapine and haloperidol treatment for schizophrenia
    M Hummer
    Department of Biological Psychiatry, Innsbruck University Clinics, Austria
    Am J Psychiatry 156:631-3. 1999
  3. ncbi request reprint Hyperprolactinaemia and antipsychotic therapy in schizophrenia
    Martina Hummer
    Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
    Curr Med Res Opin 20:189-97. 2004
  4. ncbi request reprint Attitudes of patients with schizophrenia toward placebo-controlled clinical trials
    Martina Hummer
    Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
    J Clin Psychiatry 64:277-81. 2003
  5. ncbi request reprint Selection bias in clinical trials with antipsychotics
    A Hofer
    Department of Biological Psychiatry, University Clinics Innsbruck, Austria
    J Clin Psychopharmacol 20:699-702. 2000
  6. ncbi request reprint Risk factors for the development of neuroleptic induced akathisia
    C H Miller
    Department of Biological Psychiatry, Innsbruck University Clinics, Austria
    Eur Neuropsychopharmacol 7:51-5. 1997
  7. ncbi request reprint Association of olanzapine-induced weight gain with an increase in body fat
    U Eder
    Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
    Am J Psychiatry 158:1719-22. 2001
  8. ncbi request reprint QTc variability in schizophrenia patients treated with antipsychotics and healthy controls
    Maria A Rettenbacher
    Department of Biological Psychiatry, Innsbruck University Hospital, A 6020 Innsbruck, Austria
    J Clin Psychopharmacol 25:206-10. 2005
  9. ncbi request reprint Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects
    Alex Hofer
    Department of Biological Psychiatry, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Eur Psychiatry 20:386-94. 2005
  10. ncbi request reprint Patient outcomes in schizophrenia II: the impact of cognition
    Alex Hofer
    Department of Biological Psychiatry, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Eur Psychiatry 20:395-402. 2005

Detail Information

Publications31

  1. ncbi request reprint Osteoporosis in patients with schizophrenia
    Martina Hummer
    Department of Biological Psychiatry, Innsbruck University Hospital, Austria
    Am J Psychiatry 162:162-7. 2005
    ..The authors' goals were to investigate the association between schizophrenia and a decrease in bone mineral density and to get more insight into potential underlying pathophysiological mechanisms...
  2. ncbi request reprint Sexual disturbances during clozapine and haloperidol treatment for schizophrenia
    M Hummer
    Department of Biological Psychiatry, Innsbruck University Clinics, Austria
    Am J Psychiatry 156:631-3. 1999
    ..The aim of this study was to evaluate the frequency and course of sexual disturbances associated with clozapine and haloperidol and their potential influence on compliance with medication regimens in patients with schizophrenia...
  3. ncbi request reprint Hyperprolactinaemia and antipsychotic therapy in schizophrenia
    Martina Hummer
    Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
    Curr Med Res Opin 20:189-97. 2004
    ..A regular risk-benefit discussion will allow the clinician to achieve optimal outcomes in each case...
  4. ncbi request reprint Attitudes of patients with schizophrenia toward placebo-controlled clinical trials
    Martina Hummer
    Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
    J Clin Psychiatry 64:277-81. 2003
    ..Although much is known about the opinions of professionals concerning this issue, so far nothing is known about the opinions of patients who are most affected by the realization of placebo-controlled clinical trials...
  5. ncbi request reprint Selection bias in clinical trials with antipsychotics
    A Hofer
    Department of Biological Psychiatry, University Clinics Innsbruck, Austria
    J Clin Psychopharmacol 20:699-702. 2000
    ..A history of noncompliance with previous treatment and the refusal of consent were the most common reasons for not including theoretically eligible patients in a clinical trial...
  6. ncbi request reprint Risk factors for the development of neuroleptic induced akathisia
    C H Miller
    Department of Biological Psychiatry, Innsbruck University Clinics, Austria
    Eur Neuropsychopharmacol 7:51-5. 1997
    ..75% of all NIA cases occurred within the first three days of antipsychotic treatment. When attempting to determine risk factors for the development of NIA, we found a significant influence of dose increase in the first days of treatment...
  7. ncbi request reprint Association of olanzapine-induced weight gain with an increase in body fat
    U Eder
    Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
    Am J Psychiatry 158:1719-22. 2001
    ..The goal of this study was to explore the pathophysiology of weight gain during treatment with olanzapine for schizophrenia...
  8. ncbi request reprint QTc variability in schizophrenia patients treated with antipsychotics and healthy controls
    Maria A Rettenbacher
    Department of Biological Psychiatry, Innsbruck University Hospital, A 6020 Innsbruck, Austria
    J Clin Psychopharmacol 25:206-10. 2005
    ....
  9. ncbi request reprint Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects
    Alex Hofer
    Department of Biological Psychiatry, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Eur Psychiatry 20:386-94. 2005
    ..The present cross-sectional study examined the relationships of psychopathology, side effects, and sociodemographic factors with treatment outcomes in terms of patients' quality of life (QOL), functioning, and needs for care...
  10. ncbi request reprint Patient outcomes in schizophrenia II: the impact of cognition
    Alex Hofer
    Department of Biological Psychiatry, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Eur Psychiatry 20:395-402. 2005
    ..Associations have been found between the severity of cognitive deficits and social dysfunction, impairments in independent living, occupational limitations, and disturbances in quality of life (QOL)...
  11. ncbi request reprint Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder
    Alex Hofer
    Department of Biological Psychiatry, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
    Eur Arch Psychiatry Clin Neurosci 256:246-55. 2006
    ..Our observations suggest that subjective and functional outcomes in highly compliant patients are mainly predicted by psychopathological symptoms and unchangeable sociodemographic variables...
  12. ncbi request reprint Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis
    Georg Kemmler
    Department of General Psychiatry, Innsbruck University Clinics, Anichstrasse 35, A 6020 Innsbruck, Austria
    Arch Gen Psychiatry 62:1305-12. 2005
    ..Dropout rates in randomized clinical trials of antipsychotic drugs have consistently been reported to be high, and the use of a placebo-controlled design is hypothesized to be one of the reasons for this...
  13. ncbi request reprint Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective study
    Maria A Rettenbacher
    Department of Biological Psychiatry, Medical University Innsbruck, Anichstrasse, Innsbruck, Austria
    J Clin Psychopharmacol 26:500-3. 2006
    ..We conclude that antipsychotic-induced elevation of liver enzymes is mostly transient and could be associated with weight gain...
  14. ncbi request reprint Early changes of plasma lipids during treatment with atypical antipsychotics
    Maria A Rettenbacher
    Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria
    Int Clin Psychopharmacol 21:369-72. 2006
    ..These results are important with regard to the increased risk for cardiovascular complications in patients with schizophrenia...
  15. ncbi request reprint Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study
    Maria A Rettenbacher
    Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria
    J Psychopharmacol 21:400-4. 2007
    ..None of these parameters increased significantly in patients treated with amisulpride. This study indicates that treatment with clozapine appears to have a higher risk to lead to metabolic disturbances than amisupride...
  16. ncbi request reprint Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication
    Maria A Rettenbacher
    Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
    J Clin Psychiatry 65:1211-8. 2004
    ....
  17. ncbi request reprint Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects
    Alex Hofer
    Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
    J Clin Psychiatry 65:932-9. 2004
    ..Factors deemed relevant in this context include severity of symptoms, antipsychotic-induced side effects, sociodemographic variables, and patients' subjective response to medication...
  18. ncbi request reprint Placebo or active control trials of antipsychotic drugs?
    W Wolfgang Fleischhacker
    Department of Biological Psychiatry, Innsbruck University Clinics, Austria
    Arch Gen Psychiatry 60:458-64. 2003
    ..Sample size requirements for various equivalence margins in noninferiority trials are provided. Scientific and ethical arguments should lead to a more frequent use of the active-control noninferiority trial design...
  19. ncbi request reprint The safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophrenia
    Alex Hofer
    Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
    Int J Neuropsychopharmacol 6:201-6. 2003
    ..With regard to side-effects, we could not find any significant difference between groups. Altogether, response and side-effects to clozapine treatment do not seem to be determined by the chronicity of the disorder...
  20. ncbi request reprint Factors influencing compliance in schizophrenia patients
    W Wolfgang Fleischhacker
    Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria
    J Clin Psychiatry 64:10-3. 2003
    ....
  21. ncbi request reprint Olanzapine induces insulin resistance: results from a prospective study
    Christoph F Ebenbichler
    Department of Medicine, University of Innsbruck, Innsbruck, Austria
    J Clin Psychiatry 64:1436-9. 2003
    ..The aim of this study was to compare glucose metabolism in patients with schizophrenia receiving olanzapine with that in control subjects...
  22. ncbi request reprint Off-label use of antipsychotic drugs
    E Weiss
    Department of Biological Psychiatry, University of Innsbruck, Austria
    J Clin Psychopharmacol 20:695-8. 2000
    ..In classical indications, clozapine was used more frequently (50%) than other antipsychotics. Melperone was primarily prescribed for off-label use...
  23. ncbi request reprint Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes
    W W Fleischhacker
    Innsbruck University Clinics, Department of Biological Psychiatry, Austria
    Drugs 53:915-29. 1997
    ..Long term maintenance therapy is crucial and continuous monitoring for the development of adverse effects essential...
  24. ncbi request reprint Switching between second-generation antipsychotics: why and how?
    Monika Edlinger
    Department of Biological Psychiatry, Innsbruck Medical University, Innsbruck, A 6020, Austria
    CNS Drugs 19:27-42. 2005
    ..We review the available evidence concerning techniques, problems and consequences when switching from one second-generation antipsychotic agent to another and discuss potential difficulties...
  25. ncbi request reprint The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study
    Christoph Ebenbichler
    Schizophr Res 75:143-6. 2005
  26. ncbi request reprint Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia
    Alex Hofer
    Department of Biologic Psychiatry, University Clinics Innsbruck, Austria
    J Clin Psychiatry 63:49-53. 2002
    ..A cross-sectional study was conducted in patients with schizophrenia who regularly attended an outpatient clinic to examine the impact of psychopathology, side effects, and sociodemographic factors on attitudes toward antipsychotics...
  27. ncbi request reprint The generic alternative in schizophrenia: opportunity or threat?
    Philippe Nuss
    Psychiatry Department, Hopital St Antoine, Paris 75012, France
    CNS Drugs 18:769-75. 2004
    ....
  28. ncbi request reprint Transient hyperproinsulinemia during treatment with clozapine and amisulpride
    Maria A Rettenbacher
    J Clin Psychiatry 65:878-9. 2004
  29. ncbi request reprint Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient
    Alex Hofer
    J Clin Psychiatry 64:1267-8. 2003
  30. doi request reprint Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
    Rene S Kahn
    Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, Utrecht, Netherlands
    Lancet 371:1085-97. 2008
    ..We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia...
  31. ncbi request reprint Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factors
    Markus Laimer
    J Clin Psychopharmacol 25:183-5. 2005